Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition
Transplant patients with returning liver cancer showed promising survival with combination immunotherapy while safely managing rejection risks.
This small retrospective cohort (n=15) in a challenging patient population — liver transplant recipients with HCC recurrence, typically excluded from immunotherapy trials — reports promising preliminary efficacy (median OS 36 months, ORR 60%) with lenvatinib+atezolizumab on a background of low-dose tacrolimus. ctDNA decline tracked imaging response, supporting liquid biopsy monitoring in this setting.
What the study was
- Study design
- Retrospective cohort study
- Population
- Liver transplant recipients with HCC recurrence, treated with lenvatinib + atezolizumab
- Sample size
- 15
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Pakistan Journal of Pharmaceutical Sciences
Why it surfaced
Liver transplant recipients with HCC recurrence represent a high unmet need group typically excluded from checkpoint inhibitor trials due to rejection risk. Promising efficacy signals but n=15 is insufficient for conclusions. Journal (Pak J Pharm Sci) is lower-impact; downgrade classification_confidence to medium.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.